Interpace Biosciences news

Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel (ThyGeNEXT^®) and a microRNA (miRNA) risk classifier. The new d

Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update.

Second quarter Net Revenue was $9.4 million, a 16% decrease as compared to the same period of 2021. During the second quarter the Company was notified by Novitas, it’s CME intermediary, that pricing for one of its flagship thyroid cancer screen

Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tools for personal lab automation, it will optimize next generation sequencing (NGS) library preparation utilizing its digital microfluidics (DMF) technology. Also working in conjunction with Miroculus and Interpace Biosciences will be Twist Bioscience Corporation